Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299871 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
A Phase 2 study of Type 2 Diabetes, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
- 7
- Study locations
NCT00299871 is a Phase 2 study of Type 2 Diabetes that has completed, run by Sanofi. The registered enrollment target is 542 participants, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (51% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT00299871, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
- 7
- Study locations
Study Summary
To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabetes
Conditions Studied
Interventions
- DRUG LIXISENATIDE (AVE0010)
Study Locations (7)
Other
- Sanofi-Aventis Administrative Office - São Paulo
- Sanofi-Aventis Administrative Office - Laval
- Sanofi-Aventis Administrative Office - Warsaw
- Sanofi-Aventis Administrative Office - Bucharest
- Sanofi-Aventis Administrative Office - Moscow
- Sanofi-Aventis Administrative Office - Kiev
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299871
The ClinicalTrials.gov registry entry for NCT00299871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 542 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (51% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which LIXISENATIDE (AVE0010) is the first listed.
NCT00299871 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00299871 about?
NCT00299871 is a clinical study titled "Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus". To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabetes
What is the current status of trial NCT00299871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2006-02. Estimated completion is 2007-08.
What conditions does trial NCT00299871 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00299871?
The interventions under investigation include: LIXISENATIDE (AVE0010) (DRUG).
Who is sponsoring clinical trial NCT00299871?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00299871 being conducted?
This trial has 7 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
ACTIVE NOT RECRUITING · Phase 2
-
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.